1. Early DOAC therapy within 4 days was non-inferior to delayed therapy for the composite outcome of recurrent ischemic or ...
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. This cohort study of older adults under the Medicare Advantage insurance plan demonstrated that from 2010 to 2020, there ...
1. The overall benefit of left atrial appendage occlusion (LAOO) for prevention of stroke in patients with atrial fibrillation (AF) ...
1. Asundexian 50 mg resulted in a lower rate of bleeding compared to apixaban 5 mg twice daily. 2. The ...
1. The primary efficacy outcome of symptomatic and asymptomatic venous thromboembolism was significantly lower in the rivaroxaban group (3.14%) compared ...
1. Rivaroxaban was superior to aspirin in reducing recurrent stroke or systemic embolism among patients with recent embolic stroke of ...
1. In patients treated with direct oral anticoagulants (DOACs) for atrial fibrillation or venous thromboembolism (VTE), adding aspirin (ASA) was ...
1. Direct oral anticoagulants may have a superior risk-benefit profile compared to vitamin K antagonists in atrial fibrillation for patients ...
